World's tiniest drug cabinets could be attached to cancerous cells for long term treatment

January 14, 2014

As if being sick weren't bad enough, there's also the fear of frequent injections, side effects and overdosing on you medication. Now a team of researchers from University of Copenhagen, Department of Chemistry, Nano- science center and the Institut Laue-Langevin (ILL), have shown that reservoirs of anti-viral pharmaceuticals could be manufactured to bind specifically to infected tissue such as cancer cells for the slow concentrated delivery of drug treatments.

The new research is published in ACS Macro Letters. The findings, from Dr Marité Cárdenas (Copenhagen) and Dr Richard Campbell and Dr Erik Watkins (ILL), came as a result of neutron reflectometry studies at the world's leading neutron source in Grenoble, France. They could provide a way to reduce dosages and the frequency of injections administered to patients undergoing a wide variety of treatments, as well as minimising side effects of over-dosing.

The attachment of reservoirs of therapeutic drugs to cell membranes for slow diffusion and continuous delivery inside the cells is a major aim in drug R&D. A promising candidate for packaging up and carrying such concoctions of drugs are a group of self-assembled liquid crystalline particles. Composed of fatty molecules known as phospholipids and tree-like macromolecules called dendrimers which have many branches, the particles form spontaneously and have the capacity to soak up and carry large quantities of drug molecules for prolonged diffusion. They are also known for their ability to bind to cellular membranes.

The first treatments using such particles are close to market through products incorporating a similar formulation called Cubosomes (cubic phase nanoparticles). Developed and commercialized by Swedish start-up Camarus Ab, its FluidCrystal® nanoparticles promise months of drug delivery from a single injection and the possibility of tuning the delivery to intervals of anything from daily to once monthly. However, a key requirement for optimal application of these formulations is a detailed understanding of how they interact with cellular membranes.

This was the focus of work involving a collaboration between Dr Marité Cárdenas (Copenhagen) and Dr Richard Campbell and Dr Erik Watkins (ILL). In this experiment the team used neutrons to analyse the interaction of the liquid crystalline particles with a model cellular membrane whilst varying two parameters: The team utilised a technique known as neutron reflectometry whereby beams of neutrons are skimmed off a surface and the reflectivity measured is used to infer detailed information about the surface, including the thickness, detailed structure and composition of any layers beneath. These experiments were carried out on the FIGARO instrument at the ILL in Grenoble which offers unique reflection up vs. down modes that allowed the team to examine the top and bottom surfaces, alternating the samples on a two hourly basis during a 30 hour sampling period.

The interaction of the liquid crystalline particles with the membrane was shown to be driven by the charge on the mode cell wall. Subtle changes in the amount of negative charge on the membrane wall encouraged the tree-like dendrimer molecules to penetrate through allowing the rest of the molecule to bind to the surface, forming an attached reservoir. The sensitivity of the interaction to small changes in charge suggests that simple adjustments to the proportion of charged lipids and macromolecules could optimise this process. In the future this characteristic could also provide a mechanism to focus the treatment at targeted cells such as those infected by cancer which are thought to have a more negative charge density than healthy cells.

In terms of gravitational affects the analysis also showed that the aggregates interacted preferentially with membranes only when they were located above the sample. Similar effects caused by the different density and buoyancy of solutions is already exploited in some stomach treatments and the researchers would encourage future studies into how gravitational effects could be used to optimise these interactions for drug delivery.

Quotes

"Cancerous cells have an imbalance that gives them a different molecular composition and overall different physical properties to normal healthy cells", explains Dr Cardenas. "Whilst all cells are negative, cancerous cells tend to be more negatively charged than healthy ones due to a different composition of fatty molecules on their surface. This is a property that we believe could be exploited in future research into delivery mechanisms involving the attachment of lamellar liquid crystalline particles. Our next step is to introduce the drug itself into the reservoirs and make sure it can move across the membrane. This work paves the way for cell tests and clinical trials in the future exploiting our methodology"

"Of course it's not new that particles in formulations can sink or float, but such dramatically different specific interactions of these nanocarriers with model membranes of different orientations took us completely by surprise" said Dr Campbell. "Very small sample volumes are often used in biomedical investigations so the effects of phase separation cannot be seen. Our findings suggest that laboratory researchers may need to re-evaluate the way in which they examine the effectiveness of newly developed formulations to account for strong gravitational effects."

Dr Watkins further commented: "This study is a perfect illustration of FIGARO's unique capability to take data from above and below horizontal interfaces in the same experiment. Not only are neutrons uniquely sensitive to the lighter elements found in organic chemistry but the ability to take all the data at once in situ without disturbing the sample is vital. These biological samples are always subtlety changing throughout the time you are analysing them so it's vital that you can take this data as quickly as possible."
-end-


University of Copenhagen

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.